MOTS-c Peptide Protects Rat Hearts from Ischemia-Reperfusion Injury
Background
Myocardial ischemia-reperfusion injury (IRI) is a significant complication following heart attacks or cardiac surgery, where blood flow is restored to ischemic (oxygen-deprived) heart tissue, paradoxically causing further damage. This injury can lead to cardiac dysfunction, arrhythmias, and even heart failure. Current therapeutic strategies are often insufficient to fully prevent this damage, necessitating the search for novel interventions. This study specifically investigates whether exogenous MOTS-c, a mitochondrial-derived peptide, can mitigate the cellular and functional damage associated with myocardial IRI.
Results
The administration of MOTS-c significantly improved cardiac function and reduced markers of cellular damage in the reperfused hearts. Treatment with MOTS-c at 500 nM resulted in a 45% increase in left ventricular developed pressure (LVDP) compared to untreated controls (p<0.01), indicating improved contractile function. Furthermore, MOTS-c significantly reduced infarct size, with the 500 nM group showing a 38% reduction in infarct area relative to the total ventricular area (p<0.005). This suggests MOTS-c effectively preserved myocardial integrity. The most pronounced effect was observed in the 500 nM MOTS-c group, which exhibited a 60% decrease in lactate dehydrogenase (LDH) release and a 55% reduction in creatine kinase-MB (CK-MB) levels (p<0.001), both key biomarkers of myocardial cell death, compared to the untreated IRI group. Additionally, MOTS-c treatment led to a 2.3-fold increase in antioxidant enzyme activity (e.g., superoxide dismutase) and a 35% decrease in malondialdehyde (MDA) levels, a marker of oxidative stress (p<0.01), demonstrating its protective antioxidant properties.
Why It Matters
This study provides compelling evidence that exogenous MOTS-c can effectively mitigate myocardial ischemia-reperfusion injury by preserving cardiac function, reducing infarct size, and combating oxidative stress. Given the significant morbidity and mortality associated with IRI, these findings highlight MOTS-c as a promising therapeutic candidate. If these protective effects translate to larger animal models and human studies, MOTS-c could emerge as a novel pharmacological strategy to protect patients undergoing cardiac interventions or suffering from acute myocardial infarction. Future research should focus on validating these findings in in vivo models and exploring its precise molecular mechanisms, potentially leading to Phase I clinical trials.